|Slideshows|September 19, 2019

Top Studies in Addiction: Research Recap

Prescription drug misuse in adolescents is source driven and asking frequency questions identifies problematic substance use are some of the more significant findings.

Newsletter

Receive trusted psychiatric news, expert analysis, and clinical insights — subscribe today to support your practice and your patients.

Subscribe

Related Content

Brain Trust: Carl Salzman, MD, on Benzodiazepine Mindful Prescribing, Misuse, and Dependence

ByJoseph F. Goldberg, MD,Carl Salzman, MD

August 12th 2026

Psyched Perspectives: Substance Use Awareness, A Conversation on Advocacy & Intervention

ByFrank A. Clark, MD,Chelby Drafts

July 31st 2026

Virtual Gambling Disorder Treatment Shows Rapid Symptom Improvement in New Study

ByPatrick Campbell

July 31st 2026

Podcast: Managing Co-Occurring Mood and Substance Use Disorders With Michael J. Ostacher, MD, MPH

ByJoseph F. Goldberg, MD,Michael J. Ostacher, MD, MPH

July 17th 2026

Developments in Cannabis Withdrawal and Addiction Treatment

ByGinger Constantine, MD

July 8th 2026

Latest CME

Video

(CME Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Gus Alva, MD, DFAPA; Ilan Melnick, MD

Video

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Jason Kellogg, MD; Gus Alva, MD, DFAPA; Melanie Barrett, MD; Yvette Elpidio, MSN, FNP-C

Video

Clear Skin, Clear Mind: Integrating Mental Health into Psoriasis Care

John Koo, MD; T.J. Chao, MPAS, PA-C

Video

Expert Illustrations & Commentary: Visualizing the Role of Novel Muscarinic Agents in the Management of Schizophrenia

Ilan Melnick, MD; Linda Collado, MD, DABPN, FAPA; Maria Collado, MD, FAPA

Video

(CPE Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Gus Alva, MD, DFAPA; Ilan Melnick, MD

Video

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Jason Kellogg, MD; Gus Alva, MD, DFAPA; Melanie Barrett, MD; Yvette Elpidio, MSN, FNP-C

Top Studies in Addiction: Research Recap

Related Content

Brain Trust: Carl Salzman, MD, on Benzodiazepine Mindful Prescribing, Misuse, and Dependence

Psyched Perspectives: Substance Use Awareness, A Conversation on Advocacy & Intervention

Virtual Gambling Disorder Treatment Shows Rapid Symptom Improvement in New Study

Podcast: Managing Co-Occurring Mood and Substance Use Disorders With Michael J. Ostacher, MD, MPH

Developments in Cannabis Withdrawal and Addiction Treatment

Latest CME

(CME Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Clear Skin, Clear Mind: Integrating Mental Health into Psoriasis Care

Expert Illustrations & Commentary: Visualizing the Role of Novel Muscarinic Agents in the Management of Schizophrenia

(CPE Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Trending on Psychiatric Times

DT120 (Lysergide) Shows Rapid, Lasting Relief for Generalized Anxiety in Phase 3 Trial

Experience With Xanomeline/Trospium in an Acute Inpatient Setting Treating Individuals With Schizophrenia

FDA Approves Tauklarify (MK-6240) For Tau Pathology Detection in Alzheimer Disease

New Ingrezza Data Shows Improved Quality of Life and Daily Functioning in Tardive Dyskinesia

Phase 4 Trial of Viloxazine ER Shows Real-World Gains for ADHD With Comorbid Depression, Anxiety